MedTrace Logo

PrEP Among MSM and TG in Myanmar

NCT04781426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-03-11

No results posted yet for this study

Summary

HIV is concentrated among key populations in Myanmar. Globally, HIV-prevalence among transgender (TG) women is one of the highest; laboratory-confirmed prevalence is reported up to 40%. In September 2015, WHO recommended the use of Pre-Exposure Prophylaxis (PrEP) for people at substantial risk of HIV as part of a combination HIV prevention strategy. A demonstration project will take place to implement and evaluate the uptake and effectiveness of PrEP among MSM, and TG women in a clinic in Hlaingtharyar township, Yangon. The aim is to describe PrEP uptake, as well as HIV-seroconversion and STI infection rates among those who use PrEP.

Conditions

  • HIV Infections

Interventions

DRUG

Tenofovir Disoproxil Fumarate (TDF) 300 mg

PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily

Sponsors & Collaborators

  • Medical Action Myanmar

    collaborator OTHER

  • Institute of Tropical Medicine, Belgium

    collaborator OTHER

  • Myanmar Oxford Clinical Research Unit

    lead OTHER

Principal Investigators

  • NiNi Tun, MB BS · Medical Action Myanmar

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • Burma

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04781426 on ClinicalTrials.gov